Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2275 • ACR Convergence 2023
Lupus Low Disease Activity State Ameliorates the Poor Prognosis in Lupus Nephritis Patients with anti-Sm Autoantibody
Chak Kwan Cheung¹, Chak Sing Lau² and Shirley Chiu Wai Chan³, ¹Divison of Rheumatology and Clinical Immunology, Queen Mary Hospital, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, ²University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ³Divison of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Anti-Sm autoantibody has been a known specific biomarker of systemic lupus erythematosus (SLE). There have been reports about its correlation with higher disease activity,…
Abstract Number: 2293 • ACR Convergence 2023
Recurrent Intracellular Infections Cluster Together in Patients of SLE with Lymphopenia and Active Disease
Rudrarpan Chatterjee¹, Sarit Pattanaik², Durga P Misra¹, Vikas Agarwal¹, Able Lawrence¹, Ramnath Misra³ and Amita Aggarwal¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ²SCB Medical College and Hospital, Cuttack, Odisha, Cuttack, India, ³Kalinga Institute of Medical Sciences, KIIT University, Lucknow, India
Background/Purpose: Infections are a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). We studied whether infections cluster together and which patients are…
Abstract Number: 2309 • ACR Convergence 2023
Enterococcus Gallinarum Prevalence in Patients with Systemic Lupus Erythematosus
Luis Vega Sevilla¹, Oscar E. Alvarez-González², Janett Riega-Torres³, Cassandra Michele Skinner-Taylor³, Diana Carolina Rubio Torres⁴, Lucio Vera Cabrera⁵, Dionicio A. Galarza-Delgado⁶, Jesus Alberto Cardenas-De la Garza⁷, Rodrigo J. Castillo-de la Garza⁵, Mario Alberto Aguilera Valenciano⁵, wendy Escalante⁵ and Hector Guerra⁸, ¹Hospital Universitario UANL, Garcia, Mexico, ²Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁴Faculty of Medicine and University Hospital Dr. José Eleuterio González, UANL, Monterrey, Mexico, ⁵Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁶Hospital Universitario UANL, Monterrey, Mexico, ⁷Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁸Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico
Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with epithelial defects and disrupted intestinal barrier, risking bacterial translocation, and promoting systemic inflammation, known as dysbiosis, which…
Abstract Number: 2325 • ACR Convergence 2023
Longitudinal ANA Titers in SLE and ANA-associated Rheumatic Diseases
Emily Littlejohn¹, Lingxuan Kong², Lu Wang² and Emily Somers², ¹Cleveland Clinic, Cleveland, OH, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Antinuclear antibodies (ANAs) are a hallmark of systemic lupus erythematosus (SLE) and also a marker of subclinical autoimmunity. While a seminal study using the…
Abstract Number: 2344 • ACR Convergence 2023
Telitacicept versus Belimumab for Patients with Active Systemic Lupus Erythematosus: A Retrospective, Multicenter, Real-world Observational Study
Zhu Chen¹, Huizhi Jin¹, Yujing Li¹, Guosheng Wang¹, Xiaomei Li², Zhijun Li³, Lin Niu⁴ and Haifeng Pan⁵, ¹University of Science and Technology of China, Hefei, China, ²University of Science and Technology of China, Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Hefei, China, ³Bengbu Medical University, Bengbu, China, ⁴Fuyang People's Hospital, Fuyang, China, ⁵Anhui Medical University, Hefei, China
Background/Purpose: The past decade has witnessed the innovation of several biologics in the treatment of systemic lupus erythematosus (SLE), most of which target B cells,…
Abstract Number: 2458 • ACR Convergence 2023
The Impact of Social Inequities on Presentation of Childhood-Onset Systemic Lupus Erythematosus (cSLE) at a Large Tertiary Center
Emily Beil¹, Eyal Muscal², Abiodun Oluyomi³, Omar Rosales³, Danielle Guffey⁴, Marietta DeGuzman¹, Cagri Yildirim-Toruner⁵, Andrea Ramirez³ and Erin Peckham-Gregory³, ¹Baylor College of Medicine / Texas Children's Hospital, Houston, TX, ²Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, ³Baylor College of Medicine, Houston, TX, ⁴Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, ⁵Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: The prevalence of childhood-onset SLE (cSLE) differs by racial/ethnic group. Yet, the role of social determinants of health (SDoH) in disease severity is not…
Abstract Number: 2551 • ACR Convergence 2023
Remission and Low Disease Activity (LDA) in Patients with SLE Treated with Belimumab (BEL): Results from a Large Integrated Analysis
Ioannis Parodis¹, Julius Lindblom¹, Roger A. Levy², Margherita Zen³, Nursen Cetrez¹, Alvaro Gomez⁴, Shereen Oon⁵, Christine Henning⁶, Munther Khamashta⁷, Holly A. Quasny⁸, Deven Chauhan⁹, Anca Askanase¹⁰, Ronald van Vollenhoven¹¹ and Mandana Nikpour¹², ¹Karolinska Institutet, Stockholm, Sweden, ²GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ³University of Padua, Division of Rheumatology, Department of Medicine, Padua, Italy, ⁴Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ⁵University of Melbourne at St Vincent’s Hospital, Departments of Rheumatology and Medicine, Fitzroy, Australia, ⁶GlaxoSmithKline, US Medical Affairs, Durham, NC, ⁷GSK Gulf, Medical Affairs Department, Dubai, United Arab Emirates, ⁸GlaxoSmithKline, Research & Development, Durham, NC, ⁹GlaxoSmithKline, Value Evidence and Outcomes, Brentford, United Kingdom, ¹⁰Columbia University Medical Center, New York, NY, ¹¹Amsterdam Rheumatology and Immunology Center and Amsterdam University Medical Centers, Department of Rheumatology, Amsterdam, Netherlands, ¹²The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia
Background/Purpose: A key treatment goal in SLE management is the attainment of remission or LDA,1 for which various definitions exist, including “Definitions of Remission in…
Abstract Number: 0097 • ACR Convergence 2023
Transient Ischemic Attack in Antiphospholipid Antibody-positive Patients: Retrospective and Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Zeynep Belce Erton¹, Jonathan Thaler², Danieli Andrade³, Megan Barber⁴, Maria Tektonidou⁵, Savino Sciascia⁶, Vittorio Pengo⁷, Jose Pardos-Gea⁸, Guillermo Ruiz-Irastorza⁹, Chary Lopez-Pedrera¹⁰, H Michael Belmont¹¹, Kello Nina¹², Paul R. Fortin¹³, Stéphane Zuily¹⁴, Cecilia Chighizola¹⁵, Flavio Victor Signorelli¹⁶, Zhuoli Zhang¹⁷, Tatsuya Atsuma¹⁸, Maria Efthymiou¹⁹, D. Ware Branch²⁰, Cecilia Nalli²¹, Esther Rodriguez almaraz²², Michelle Petri²³, Giulia Pazzola²⁴, Ricard Cervera²⁵, Bahar Artim Esen²⁶, Hui Shi²⁷, Yu Zuo²⁸, Rosana M Quintana²⁹, Rohan Willis³⁰, Ali Duarte-Garcia³¹, Maria Laura Bertolaccini³², Hannah Cohen³³, Doruk Erkan² and On Behalf Of APS ACTION³⁴, ¹SUNY Downstate Medical Center, Brooklyn, NY, ²Hospital for Special Surgery, New York, NY, ³University of São Paulo, São Paulo, Brazil, ⁴University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ⁵Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁶University of Turin, Torino, Italy, ⁷Department of Cardiac-Thoracic-Vascular Sciences and Public Health University of Padova, Padova, Italy, ⁸Vall d'Hebron University Hospital, Barcelona, Spain, ⁹Hospital Universitario Cruces, Barakaldo, Spain, ¹⁰IMIBIC - Reina Sofia Hospital, Córdoba, Spain, ¹¹NYU School of Medicine, New York, NY, ¹²Northwell Health, Brooklyn, NY, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁴Lorraine University, Vandoeuvre-lès-Nancy, France, ¹⁵University of Milan, Milan, Italy, ¹⁶University of São Paulo, Rio De Janeiro, Brazil, ¹⁷Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁸Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ¹⁹University College London, London, United Kingdom, ²⁰University of Utah, Salt Lake City, UT, ²¹Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, ²²Hospital Universitario 12 de Octubre, Madrid, Spain, ²³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁴Azienda Ospedaliera Santa Maria Nuova di Reggio Emilia, Reggio Emilia, Italy, ²⁵Hospital Clínic de Barcelona, Barcelona, Spain, ²⁶Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²⁷Rijin Hospital, Shanghai, China, ²⁸University of Michigan, Ann Arbor, MI, ²⁹Centro Regional de Enfermedades Autoinmunes y Reumticas (CREAR), Grupo Oroño, Rosario, Argentina, ³⁰University of Texas Medical Branch, Galveston, TX, ³¹Mayo Clinic, Rochester, MN, ³²King's College London, London, United Kingdom, ³³University College London Hospitals NHS Foundation Trust, London, United Kingdom, ³⁴on behalf of APS ACTION, New York, NY
Background/Purpose: APS ACTION Registry aims to study the course of disease in antiphospholipid antibody (aPL)-positive patients. Although transient ischemic attack (TIA) can develop in aPL-positive…
Abstract Number: 0182 • ACR Convergence 2023
Impact of Neighborhood-level Child Opportunity on Disease Activity in Children with Lupus
Joyce Chang¹, Gabrielle Alonzi¹, Emily Smitherman², Pooja Patel³, Gabrielle Morgan⁴, Livie Huie⁵, Karen Costenbader⁶ and Mary Beth Son⁷, ¹Boston Children's Hospital, Boston, MA, ²University of Alabama at Birmingham, Birmingham, AL, ³Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵University of Alabama at Birmingham, Gardendale, AL, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Racial disparities in outcomes of pediatric SLE (pSLE) have persisted over time. This may be mediated by structural racism, which segregates children belonging to…
Abstract Number: 0461 • ACR Convergence 2023
Self-esteem as a Determinant of Sexual Function in SLE Patients
María Espinosa-León¹, Daniela Marengo-Rodríguez², Monserrat Ibarra-Velasco², Ana Barrera-Vargas² and Javier Merayo-Chalico³, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City, Mexico, ³Reumátika, Centro de Vanguardia en Reumatología de la Ciudad de México, Mexico City, Mexico
Background/Purpose: Rheumatic diseases, and specifically SLE, present with greater sexual dysfunction than other chronic diseases. Sexual dysfunction (SxD) is multifactorial and comprises disease-related factors, psychological…
Abstract Number: 0553 • ACR Convergence 2023
Serum Isolevuglandin IgG Antibody Concentrations Are Increased in Patients with Systemic Lupus Erythematosus versus Control Subjects and Associated with Lower 24-hour Blood Pressure
Anastasiia Phothisane¹, Shahensha Shaik¹, Qiong Wu¹, Olivia Posey¹, Sean Davies², Jaya Krishnan¹, David Patrick³, C. Michael Stein¹ and Michelle Ormseth¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University, Nashville, TN, ³Department of Veterans Affairs, Nashville, TN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a 2-3-fold increased risk of cardiovascular events. A major risk factor for this is hypertension. We previously…
Abstract Number: 0570 • ACR Convergence 2023
BLyS Levels Are Elevated in Systemic Lupus Erythematosus Patients with Neuropsychiatric Manifestations
Ana Carolina Alencar¹, Taís Mazzola¹, Samara Sepresse¹, Bruna Aquino¹, Isadora Teixeira¹, Isadora Ribeiro¹, Liara Rizzi¹, Ítalo Aventurato¹, Marjorie Da Silva¹, Marcio Balthazar¹, Lilian Costallat¹, Roberto Marini², Luciana Silva¹, Clarissa Yasuda¹, Fernando Cendes¹, Timothy Niewold³ and Simone Appenzeller¹, ¹UNICAMP, Campinas, Brazil, ²Revista Brasileira de Reumatologia, Campinas, Brazil, ³Hospital for Special Surgery, New York, NY
Background/Purpose: Autoantibodies and auto reactive B cells participate on the pathogenesis of systemic lupus erythematosus (SLE), affecting various organs and tissues, including the nervous system,…
Abstract Number: 0588 • ACR Convergence 2023
Long Term Safety and Predictors of Serious Infections Among Patients with Systemic Lupus Erythematosus Treated with Rituximab: Audit from a Single Center Biologic Registry
Augustine Jose¹, Aishwarya Gopal¹, Mamatha Gorijavolu¹, Anna C Das², Jagan Babu K L¹, Amrita Nayak¹, Chengappa Kavadichanda¹ and Molly Mary Thabah¹, ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ²St.Johns National Academy of Health Sciences, Bengaluru, India
Background/Purpose: Rituximab (RTX) is increasingly being employed to treat refractory systemic lupus erythematosus(SLE). Though the drug is effective there is a high risk of adverse…
Abstract Number: 0607 • ACR Convergence 2023
CAR T Cell Therapy Leads to Long-term Abrogation of Autoimmunity in SLE Patients While Vaccination Responses Are Maintained
Georg Schett¹, Luis Munoz², Jule Taubmann³, Michael Aigner⁴, Christina Bergmann⁵, Johannes Knitza⁶, Gerhard Kroenke⁷, Dagmar Werner², Fabian Müller⁸ and Andreas Mackensen⁴, ¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ²FAU Erlangen-Nürnberg, Erlangen, Germany, ³Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁴Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁵Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁶Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ⁷Charite Berlin, Berlin, Germany, ⁸Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: We have previously shown that CD19 CAR T cell therapy leads to stable drug-free remission of treatment-resistant SLE (1,2). Based on these findings we…
Abstract Number: 0828 • ACR Convergence 2023
Item Reduction and Validation of the Cutaneous Lupus Erythematosus Quality of Life Questionnaire
Maya Adams¹, Linda Hynan², Motolani Ogunsanya³ and Benjamin Chong¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Peter O’Donnell Jr. School of Public Health and Department of Psychiatry, Dallas, TX, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Cutaneous lupus erythematosus (CLE) symptoms often require patient-reported outcome measures (PROMs) to monitor disease progression. The CLE quality of life (CLEQoL) instrument was devised…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].